clinical trial · NCT04928677
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
Primary Extra-cranial Solid TumorRecurrent or Refractory Glypican 3 (GPC3)Codrituzumab
brief summary
The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, and cleared from the body.
started
Jun 9, 2021
primary completion
Jun 1, 2027
completion
Jun 1, 2027
last updated
Oct 26, 2026
official title
A Multi-Center Phase I Study of Codrituzumab in Pediatric Patients With Relapsed or Refractory Glypican 3 (GPC3) Expressing Extra-cranial Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol